BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

NCT03482635 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: Spesolimab
DRUG: Placebo

Sponsor

Boehringer Ingelheim